FCM
CBIO

Farallon Capital Management’s Crescent Biopharma CBIO Stock Holding History

Farallon Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,500
Closed -$4.06M – 98
2018
Q1 		$4.06M Buy
+2,500
New +$5.2M 0.03% 83

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Farallon Capital Management's CBIO Position: Q2 2018 in Review

Farallon Capital Management sold out of Crescent Biopharma (CBIO) in Q2 2018, closing a stake of 2,500 shares — an estimated $4.06M sold.

Farallon Capital Management first reported a position in CBIO in Q1 2018 and held it in 1 quarter. The position peaked at $4.06M in Q1 2018. 84 funds tracked by Wall St. Rank hold CBIO as of Q2 2018.

  • Farallon Capital Management reported no remaining Crescent Biopharma position as of Q2 2018 after selling out during the quarter.
  • Farallon Capital Management sold 2,500 Crescent Biopharma shares in Q2 2018, an estimated $4.06M.
  • Farallon Capital Management first reported a position in Crescent Biopharma in Q1 2018 and held it in 1 quarter.
  • Farallon Capital Management's Crescent Biopharma position peaked at $4.06M in Q1 2018.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2018.

Based on Farallon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.